Caribou Biosciences (CRBU) CTO sells 6,228 shares in open-market trade
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Caribou Biosciences, Inc. Chief Technology Officer Timothy P. Kelly reported an open-market sale of 6,228 shares of common stock at $1.93 per share. After this February 25, 2026 transaction, he directly owns 73,125 shares of Caribou Biosciences common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 6,228 shares ($12,020)
Net Sell
1 txn
Insider
Kelly Timothy P
Role
Chief Technology Officer
Sold
6,228 shs ($12K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,228 | $1.93 | $12K |
Holdings After Transaction:
Common Stock — 73,125 shares (Direct)
Footnotes (1)
FAQ
What insider transaction did Caribou Biosciences (CRBU) report for Timothy P. Kelly?
Caribou Biosciences reported that Chief Technology Officer Timothy P. Kelly sold 6,228 shares of common stock. The sale was an open-market transaction at $1.93 per share on February 25, 2026, as disclosed in a Form 4 filing.
What role does Timothy P. Kelly hold at Caribou Biosciences (CRBU)?
Timothy P. Kelly serves as Chief Technology Officer at Caribou Biosciences. His position is identified in the Form 4 filing, which reports his insider status and the details of his open-market sale of 6,228 shares of common stock at $1.93 per share.
Was the Caribou Biosciences (CRBU) insider transaction a buy or a sell?
The transaction was a sale of common stock. The Form 4 classifies it with code “S,” indicating a sale in an open market or private transaction, and shows 6,228 shares sold at $1.93 per share by Timothy P. Kelly.
Is Timothy P. Kelly’s Caribou Biosciences (CRBU) ownership direct or indirect?
Timothy P. Kelly’s reported holdings are classified as direct ownership. The Form 4 lists the ownership code as “D,” indicating that the 73,125 shares he holds following the 6,228-share sale are owned directly, with no separate entity attribution disclosed.